Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...

Kymera Therapeutics’ growing roster of partnerships continues to reinforce its long-term value, according to Oppenheimer, despite a setback in one of its programs.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics, Inc. announced the pricing of its public offering of $250.8 million, consisting of 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants for ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Kymera Therapeutics Announces Pricing of $250 Million Public Offering Provided by GlobeNewswire Jun 27, 2025, 3:56:15 AM. WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera ...

A high-level overview of Kymera Therapeutics, Inc. (KYMR) stock. View (KYMR) real-time stock price, chart, news, analysis, analyst reviews and more.

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of ora ...